Aktis Oncology, Inc. AKTS 深 沪
等待开盘 04-03 09:30:00 美东时间
17.37
+0.300
+1.76%
华盛通- 最 高17.46
- 今 开16.71
- 成交量 32.89万股
- 最 低 16.25
- 昨 收 17.07
- 总市值 9.60亿
- 52周最高 29.16
- 市盈率 静 --
- 换手率 0.59%
- 52周最低 14.72
- 委 比 33.55%
- 总股本 5527.60万
- 历史最高 29.16
- 量 比 0.58
- 振 幅 7.09%
- 历史最低 14.72
- 每 手 1
- 风险率 1.47%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 存储分歧大！花旗大砍17%将美光目标价从510降至425美元；Bernstein上调希捷科技目标价从500升至620美元
今日重点评级关注：Maxim Group：上调Theriva Biologics评级至"买入"，目标价1美元；HC Wainwright & Co.：维持Bicara Therapeutics"买入"评级，目标价从40美元升至42美元
04-01 16:34
Aktis Oncology Announces FDA Clearance of Investigational New Drug Applications for AKY-2519 and Provides Business Updates and Full Year 2025 Financial Results
Aktis Oncology announced FDA clearance of IND applications for AKY-2519, a miniprotein radioconjugate targeting B7-H3, enabling Phase 1b clinical trials to begin mid-2026 for solid tumors including prostate and lung cancers. AKY-2519 joins AKY-1189, targeting Nectin-4, currently in Phase 1b trials for multiple cancers. The company highlighted its proprietary platform for delivering actinium-225 with high tumor selectivity. Key milestones include ...
03-30 20:01
美股大行评级 | 潜在涨幅148%！瑞银、小摩等8家大行首予SOLV Energy买入评级目标价42美元；甲骨文绩前遭德银等下调目标价；京东遭巴克莱下调目标价
今日重点评级关注：Evercore ISI集团：维持Caribou Biosciences"跑赢大市"评级，目标价从11美元升至13美元；富国银行：上调uniQure评级至"超配"，目标价从15美元升至60美元
03-10 15:05
HC Wainwright & Co. Initiates Coverage On Aktis Oncology with Buy Rating, Announces Price Target of $30
HC Wainwright & Co. analyst Robert Burns initiates coverage on Aktis Oncology (NASDAQ:AKTS) with a Buy rating and announces Price Target of $30.
03-09 18:22
Aktis Oncology's AKY-1189 Receives FDA Fast Track Designation
U.S. FDA Fast Track designation granted to AKY-11891 for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have progressed on or after prior systemic therapiesOngoing Phase 1b
02-24 21:11
Aktis Oncology Receives U.S. FDA Fast Track Designation for AKY-1189, a Nectin-4 Miniprotein Radioconjugate
Aktis Oncology's AKY-1189 has been granted U.S. FDA Fast Track designation for treating adults with locally advanced or metastatic urothelial cancer (mUC) who have failed prior systemic therapies. AKY-1189, developed using Aktis’ miniprotein radioconjugate platform, targets Nectin-4-expressing tumors, seen in 80-90% of urothelial cancer patients. The designation aims to expedite development and review for serious conditions with unmet needs. Akti...
02-24 13:00
美股大行评级 | 潜在涨幅213.87%！Wave Life Sciences获Canaccord Genuity升目标价至43美元，维持"买入"评级
今日重点评级关注：Canaccord Genuity：维持Wave Life Sciences Ltd."买入"评级，目标价从40美元升至43美元；花旗：维持Palantir Technologies"买入"评级，目标价从235美元升至260美元
02-04 12:15
Leerink Partners Initiates Coverage On Aktis Oncology with Outperform Rating, Announces Price Target of $31
Leerink Partners initiates coverage on Aktis Oncology (NASDAQ:AKTS) with a Outperform rating and announces Price Target of $31.
02-03 20:29
JP Morgan Initiates Coverage On Aktis Oncology with Overweight Rating, Announces Price Target of $30
JP Morgan analyst Jessica Fye initiates coverage on Aktis Oncology (NASDAQ:AKTS) with a Overweight rating and announces Price Target of $30.
02-03 20:27
Aktis Oncology Closes Upsized IPO Of 17.65M Common Shares At Price Of $18.00 Per Share, Occurred On January 12, 2026
Aktis Oncology, Inc. ("Aktis"), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing
01-13 19:35
